Followers | 42 |
Posts | 5751 |
Boards Moderated | 0 |
Alias Born | 04/12/2021 |
Monday, September 12, 2022 7:38:35 AM
“4:13a ET 9/10/2022 - Globe Newswire
Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody(R) ADG126 in Patients with Advanced Tumors”
Yes technically a couple of patients had anti-tumor activity, but the headline can easily be misconstrued and read at first glance to infer that all patients had that positive reaction. The headline should be clear, naming the exact number of patients who experienced tumor reduction out of the total number of patients, if they want to claim that a build up of ADG in the tumors is anti-tumor activity then that is different “activity” than tumor reduction, if I paint mayonnaise every day on non-reducing tumors of a patient over the course of 6 months, mayonnaise would also safely show up in trial results accumulating in the area.
my posts are always theory and not financial advice
Recent ADAG News
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 09/24/2024 02:26:03 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/16/2024 01:21:10 PM
- Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC • GlobeNewswire Inc. • 09/16/2024 07:01:00 AM
- Adagene to Participate in Investor Conferences in September • GlobeNewswire Inc. • 08/29/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/25/2024 08:05:54 PM
- Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update • GlobeNewswire Inc. • 07/25/2024 08:05:00 PM
- Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September • GlobeNewswire Inc. • 07/12/2024 11:00:00 AM
- Adagene to Present at Investor Conferences in June • GlobeNewswire Inc. • 05/22/2024 08:45:00 PM
- Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/29/2024 01:00:00 PM
- Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board • GlobeNewswire Inc. • 03/07/2024 09:01:00 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 03/01/2024 09:30:20 PM
- Adagene to Present at the Leerink Partners Global Biopharma Conference 2024 • GlobeNewswire Inc. • 02/27/2024 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/09/2024 11:08:42 AM
- Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stab • GlobeNewswire Inc. • 02/09/2024 11:00:00 AM
- Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) • GlobeNewswire Inc. • 01/16/2024 10:01:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/16/2024 10:00:13 PM
- Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium • GlobeNewswire Inc. • 01/04/2024 10:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/03/2023 04:00:43 PM
- Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023 • GlobeNewswire Inc. • 11/03/2023 04:00:00 PM
- Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting • GlobeNewswire Inc. • 10/12/2023 12:00:00 PM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM